This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.
Dana Rathkopf, MD
Advertisement
Articles by Dana Rathkopf, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
2
FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer
3
Experts Analyze 6-Year Zanubrutinib Data Across CLL/SLL Settings
4
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
5